-
InnoCare Announces Inclusion of Orelabrutinib’s New Indication in China National Reimbursement Drug List 2023
PharmaSources
December 14, 2023
InnoCare Pharma announced today the inclusion of new indication of BTK inhibitor orelabrutinib in the updated National Reimbursement Drug List 2023.
-
ANTABIO Raises €25 Million in Series B Financing
B3C newswire
December 13, 2023
Antabio SAS announced today that it has raised €25m in a series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from the company’s historical investors including BNP Paribas Développement.
-
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
PharmaSources
December 11, 2023
InnoCare Pharma announced today that the latest data from InnoCare's oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
-
Vetter Joins Science Based Targets Initiative (SBTi)
B3C newswire
December 06, 2023
Vetter, a leading globally operating Contract Development and Manufacturing Organization (CDMO), has joined the Science Based Targets Initiative (SBTi) membership group as of November 2023. 2023.
-
MIMETAS and Yamaha Motor Sign Joint Marketing Agreement to Advance Automated Human Disease Model Applications for Drug Development
B3C newswire
November 30, 2023
MIMETAS, a leader in human 3D disease modeling, and Yamaha Motor Co., Ltd., a developer of the CELL HANDLER™, announce a strategic joint marketing agreement
-
Coriolis Pharma Re-Establishes Chair in Vaccine Development at Leiden University
B3C newswire
November 16, 2023
Coriolis Pharma Research today announced that the Special Chair in Vaccine Development at Leiden University has been re-awarded to Prof. Dr. Gideon Kersten, Scientific Advisor at Coriolis Pharma.
-
Vetter’s European Clinical Site Receives Permanent Manufacturer’s Authorization
B3C newswire
November 16, 2023
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria.
-
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases
B3C newswire
November 16, 2023
SciRhom GmbH, a pioneering biotech enterprise specialized in developing first-in-class therapeutic antibodies, announced today the achievement of a significant milestone in its development pipeline.
-
Verici DX Plc Reaches a Global Licensing and Commercialisation Agreement with Thermo Fisher Scientific
B3C newswire
November 16, 2023
Verici Dx plc,today announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.
-
4D Lifetec Secures CHF 23.3 Mio in a Share and Investment Deal with Xlife Sciences Opening New Horizons in Using AI and Digital Health in Early Cancer Detection
B3C newswire
November 06, 2023
In a significant financial milestone, Xlife Sciences AG invests CHF 23.3 million in 4D Lifetec AG, acquiring a 20% stake in the company.